α-Synuclein--chaperone interaction at atomic detail {#S1}
===================================================

Based on previous findings that molecular chaperones share common patterns of client recognition^[@R10],[@R11]^, we characterized the interactions of an array of molecular chaperones with α-Synuclein. The array included human Hsc70 and Hsp90β, and bacterial chaperones SecB, Skp, SurA, and Trigger Factor, featuring strongly diverse architectures^[@R10]^. Any of these chaperones interferes functionally with α-Synuclein aggregation in a Thioflavin T (ThT) assay^[@R6],[@R8],[@R12]^, already at 1:20 sub-stoichiometry, and with stronger effects at 1:10 ratios ([Figs. 1a--c](#F1){ref-type="fig"}). The known Hsp90β inhibitors Geldanamycin and Radicicol (referred to onwards as drugs) decreased the chaperoning effect of Hsp90β ([Fig. 1c](#F1){ref-type="fig"}), in line with the known mechanism of these drugs^[@R13],[@R14]^. We determined the segments of α-Synuclein interacting with the individual chaperones at the atomic level by measuring NMR signal intensity attenuations and chemical shift perturbations in 2D \[^15^N,^1^H\]-NMR spectroscopy. For all six chaperones, the effects were most pronounced for twelve amino acid residues at the N-terminus and for six residues around Tyr39, indicating a direct albeit transient intermolecular interaction *via* these two segments, which are thus identified as the canonical chaperone-interaction motif of α-Synuclein ([Fig. 1d--g](#F1){ref-type="fig"}; [Extended Data Figs. 1](#F5){ref-type="fig"},[2](#F6){ref-type="fig"}). Inhibiting Hsp90β by drugs affected the interaction with α-Synuclein partially and for Hsc70 the interaction was observed in the ADP-- and the ATP--bound, but not in the apo--state ([Fig. 1g](#F1){ref-type="fig"}; [Extended Data Fig. 3](#F7){ref-type="fig"}), in line with earlier reports^[@R6],[@R15],[@R6],[@R16]^ (see [Supplemental discussion](#SD12){ref-type="supplementary-material"}). Importantly, for all six chaperones, the interaction is observed at protein concentrations of 100 μM, far away from possible non-specific effects of macromolecular crowding. We probed such non-specific effects with high concentrations of either bovine serum albumin (BSA) or ubiquitin. No signal attenuations were observed for 150--310 mg/ml ubiquitin, ruling out macromolecular crowding effects. For high concentrations of BSA the canonical chaperone interaction signature is observed ([Fig. 1g](#F1){ref-type="fig"}; [Extended Data Figs. 3d--j](#F7){ref-type="fig"}), due to BSA's weak molecular chaperone function^[@R17]^. Together, the experiments on an array of six chaperones and two control proteins revealed a canonical chaperone interaction for α-Synuclein at the amino-terminus and around Tyr39, transient in nature. Notably, it comprises the two locally most hydrophobic segments of α-Synuclein ([Extended Data Fig. 3k,l](#F7){ref-type="fig"}), indicating an importance of hydrophobic residues for the chaperone interaction.

Towards characterizing the physiological role of chaperone--α-Synuclein interactions, we determined the affinity of α-Synuclein to Hsc70~ADP~, SecB, and Skp by Bio-Layer Interferometry (BLI). α-Synuclein binds each of these chaperones with affinities ranging 1--2 μM ([Extended Data Fig. 4](#F8){ref-type="fig"} and [Supplementary Table S1](#SD2){ref-type="supplementary-material"}). The variant ∆N--α-Synuclein lacking 10 amino-terminal residues, has an affinity decreased by two orders of magnitude, validating this segment as part of the interaction site. At the reported cellular concentrations of α-Synuclein in neuronal synapses of \~50 μM with a combined concentration of Hsp70/Hsp90 chaperones of \~70μM^[@R18]^, about 90% of cellular α-Synuclein can thus be chaperone-bound.

We then analyzed published data on the NMR intensity profile of α-Synuclein inside living mammalian cells, which strikingly feature the canonical chaperone interaction signature^[@R9]^. Because this pattern was suggested to arise from interactions with cellular membranes, we probed the interaction of α-Synuclein with soluble cellular extracts. α-Synuclein in either 25 mg/ml *E. coli* cell-extract or 50 mg/ml soluble extracts from two mammalian cell lines, HEK-293 or MDCK-II, showed the canonical chaperone interaction pattern ([Fig. 1h](#F1){ref-type="fig"}; [Extended Data Figs. 5a--d](#F9){ref-type="fig"}), thus experimentally reproducing the in-cell interaction pattern in the absence of membranes^[@R9]^. Furthermore, we characterized the interaction pattern of α-Synuclein with lipid bilayer membranes *in vitro*^[@R19]^. Titrating LUVs (Large unilamellar vesicles) to α-Synuclein in a 125:1 lipid:protein ratio lead to a uniform NMR signal decrease for residues 1--90 ([Extended Data Fig. 6a](#F10){ref-type="fig"}), in full agreement with published reports^[@R9],[@R19]^. Adding 2--6 equivalents of SecB to α-Synuclein--LUV solutions restored the chaperone signature, whereas the reverse experiment, addition of LUVs to an existing SecB--α-Synuclein complex led to global signal attenuation for residues 1--90 with substantially reduced effect, indicating that LUVs and SecB mutually compete for α-Synuclein binding ([Extended Data Fig. 6](#F10){ref-type="fig"}). Overall, α-Synuclein thus populates an equilibrium between its free state, its membrane-bound state, and its chaperone-bound state, with the latter two being mutually exclusive. The emerging hypothesis that in mammalian cells α-Synuclein is dominantly in contact with chaperones rather than with lipid bilayers was supported by an experimental determination of the interactome of the α-Synuclein amino-terminus in mammalian cells by chemical cross-linking and mass-spectrometry. The interactome consists of a large number of molecular chaperones in the range of 30--75% abundance, including several Hsp90-variants and six Hsp70-variants ([Fig. 2a](#F2){ref-type="fig"}; see [Supplemental](#SD12){ref-type="supplementary-material"} for details).

In-cell NMR spectroscopy {#S2}
========================

Next, we carried out in-cell NMR experiments to study the interaction of α-Synuclein with chaperones inside living mammalian cells at atomic resolution. \[*U*-^15^N\]--α-Synuclein was delivered into HEK-293 cells at a concentration of 3--10 μM, yielding intensity patterns characteristic for mammalian cell-lines^[@R9]^ ([Figs. 2b--c](#F2){ref-type="fig"}), comprising the canonical chaperone--interaction signature and its transient nature. Multiple molecular chaperones are present in the cell, with mutually overlapping functions and "clientomes"^[@R20]^. In line with our *in vitro* chaperone array, we probed the two constitutively most expressed eukaryotic chaperones Hsc70 and Hsp90β. When \[*U*-^15^N\]--α-Synuclein was delivered into cells with reduced Hsc70 levels ([Extended Data Figs. 7c,d](#F11){ref-type="fig"}), the NMR intensity profile resembled the one observed for normal cells, suggesting a functional redundancy with other cellular chaperones ([Figs. 2d,e](#F2){ref-type="fig"}). Next, we treated cells with the Hsp90-inhibiting drugs, and found that the canonical chaperone interaction motif showed increased intensities compared to untreated cells ([Fig. 2d](#F2){ref-type="fig"}). This suggests that Hsp90 chaperones physically interact with α-Synuclein in normal cells transiently, and that this interaction is lost upon drug treatment. Immunoprecipitation assays confirmed an almost complete loss of this interaction at 24 hours post-treatment ([Extended Data Fig. 7e](#F11){ref-type="fig"}). Finally, we inhibited both Hsc70 and Hsp90β chaperones simultaneously, observing a moderate effect on the canonical interaction motif already at 4 hours post-treatment, when a significant fraction of Hsp90 still remains bound to α-Synuclein ([Extended Data Fig. 7e](#F11){ref-type="fig"}). At this time point, a low but measurable amount of free intracellular α-Synuclein was observed ([Fig. 2d](#F2){ref-type="fig"}). At 24 hours post-treatment, a dramatic global signal reduction for residues 1--90 was observed, essentially identical to the LUV interaction pattern, as well as to the profile reported for α-Synuclein binding bacterial membranes^[@R19],[@R21]^ ([Figs. 2d,f](#F2){ref-type="fig"}). The combined inhibition of the two chaperones types Hsc70 and Hsp90 thus leads to a transient membrane interaction of α-Synuclein, absent in the cellular ground state. In parallel, upon suppressing both chaperones we observed the formation of macroscopic aggregates containing α-Synuclein ([Extended Data Figs. 7f](#F11){ref-type="fig"}). Overall, these in-cell NMR and *in vitro* experiments show that in normal cells α-Synuclein is physically and transiently interacting with a pool of constitutively expressed chaperones and that this interaction dominates over α-Synuclein's transient interaction with membranes. In typical cells including neurons^[@R18],[@R22]^, as well as in our in-cell experiments the concentration of chaperones is substantially larger than the concentrations of α-Synuclein, underlining the physiological relevance of these observations ([Extended Data Figs. 7g,h](#F11){ref-type="fig"}).

Intracellular membrane localization {#S3}
===================================

The interaction of α-Synuclein with cellular membranes upon Hsc70/Hsp90 inhibition may be a key mechanism for disease pathogenesis and we thus aimed at identifying the involved membranous organelle by co-localization. To this end, control cells and HEK-293 cells depleted of Hsc70 and treated with drugs for 24 hours, stained with mitotracker (stains mitochondria), lysotracker (stains acidic vesicles, e.g. lysosomes), or Alexa-Fluor-labeled wheat germ agglutinin (WGA, stains plasma membrane and endoplasmic reticulum), and subsequently immunostained with anti-α-Synuclein antibodies. These experiments revealed a strong co-localization of α-Synuclein with mitochondria upon depletion of chaperones ([Fig. 3a--c](#F3){ref-type="fig"}). To further confirm this association, we carried out immunofluorescence analyses using antibodies specific for the mitochondrial marker CoxIV and α-Synuclein ([Fig. 3d](#F3){ref-type="fig"}), as well as the mitochondrial marker mtBFP (mitochondrial blue fluorescent protein) in control and in HEK-293 cells with impaired Hsc70 and Hsp90 activity ([Figs. 3e,f](#F3){ref-type="fig"}). Both additional approaches confirmed the localization of α-Synuclein to mitochondria upon chaperone inhibition.

Effect of posttranslational modifications {#S4}
=========================================

Having established the canonical chaperone interaction signature, and validated its presence in living cells, we investigated the effect of chemical modifications on the α-Synuclein--chaperone interaction. Using the chaperones Hsp90β, Hsc70~ADP~, SecB, and Skp, we probed the effects of amino-terminal acetylation of α-Synuclein, the predominant form in mammalian cells^[@R9],[@R19]^. Acetylation does not interfere with the chaperone interaction ([Fig. 4](#F4){ref-type="fig"}; [Extended Data Figs. 8a--g](#F12){ref-type="fig"}). In contrast, ∆N--α-Synuclein features a completely reduced interaction with all chaperones, in full agreement with the BLI experiments, and revealing a synergistic effect between the amino-terminus and the stretch around Tyr39 ([Figs. 4b--e](#F4){ref-type="fig"}). Cellular oxidative stress and reactive oxygen species imbalance are known hallmarks of Parkinson's disease onset, leading to oxidative modification of α-Synuclein^[@R2]^. Titrating of Hsp90β, Hsc70~ADP~, SecB or Skp to methionine-oxidized α-Synuclein^[@R23]^ showed that oxidation of Met1 and Met5 abolish the amino-terminal interaction ([Fig. 4](#F4){ref-type="fig"}, [Extended Data Fig. 9](#F13){ref-type="fig"}). To explore the effects of phosphorylation on chaperone interaction, we employed *in vitro* tyrosine-phosphorylation with different kinases^[@R5],[@R24]^ ([Fig. 4](#F4){ref-type="fig"}; [Extended Data Fig. 9](#F13){ref-type="fig"}). Titration of SecB, Skp, Hsp90β, or Hsc70~ADP~ to either tetra-phosphorylated or Tyr39-mono-phosphorylated α-Synuclein resulted in elimination of the chaperone interaction, whereas Tyr125-Tyr133-Tyr136-tri-phosphorylated α-Synuclein showed the chaperone interaction pattern of unmodified α-Synuclein ([Fig. 4](#F4){ref-type="fig"}). Tyr39 phosphorylation thus has a specific inhibitory effect towards chaperone interaction, providing a direct rationale for *in vivo* studies showing that up-regulation of c-Abl correlates strongly with Tyr39-phosphorylation and disease progression in Parkinson's disease^[@R5],[@R25]^.

Conclusion {#S5}
==========

Overall, in this work we have identified a functional mechanism for regulation of α-Synuclein by chaperones in mammalian cells through transient binding ([Extended Data Fig. 10](#F14){ref-type="fig"}). Molecular chaperones bind the IDP α-Synuclein *via* a canonical motif, based on recognizing intrinsic biophysical features. The interaction vanishes upon inhibition of two main chaperones, resulting in transient membrane interactions and an accumulation of α-Synuclein at mitochondria, a major component of Lewy bodies^[@R26],[@R27]^. A functional model emerges, where transient chaperone-interacting forms are the dominant species of α-Synuclein in healthy cells, making chaperones a master regulator of the cellular states of α-Synuclein. It predicts that changes in the cellular levels of either chaperones or α-Synuclein, or the modulation of their interaction will disturb the homeostatic balance, eventually causing Parkinson's disease. Notably, this model agrees with a plethora of reported experimental observations (see [Supplemental](#SD12){ref-type="supplementary-material"} for an extended discussion), including that the ratio of α-Synuclein to chaperone is impaired by familial Parkinsonism and that oxidative stress can lead to an increase of α-Synuclein Tyr39-phosphorylation^[@R5],[@R25]^, which interferes with chaperone binding. The model shows further how modulation of chaperone activity might prevent the formation of oligomeric α-Synuclein, leading to mitochondrial membrane disruption^[@R28]^ and also accounts for recent reports that impairment of mitochondria may constitute an important factor in Parkinson's disease^[@R29]--[@R31]^.

Extended Data {#S6}
=============

![Interaction between α-Synuclein and bacterial chaperones.\
**a--c,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 250 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 500 μM chaperones, as indicated. The sequence-specific assignments for significantly affected resonances are indicated. **d,** Residue-resolved chemical shift perturbations of α-Synuclein caused by the addition of two equivalents of either SecB-tetramer (yellow), Trigger Factor dimer (orange), Skp trimer (red), and SurA dimer (dark red). Broken lines indicate a significance level of two standard deviations of the mean. **e,** Temperature-dependence of the α-Synuclein interaction with either SecB (yellow) or Skp (red) monitored by residue-resolved intensity ratios (*I*~rel~ = *I*/*I*~0~) of ^13^C-direct detected 2D \[^15^N,^13^C\]--NMR spectra. The intensity ratios of 2D \[^15^N, ^1^H\]--NMR spectra at 281 K ([Fig. 1**c**](#F1){ref-type="fig"}) are shown as an outline (grey). **f, g,** Overlay of 2D \[^13^C,^15^N\]-NMR spectra of 500 μM \[*U*-^13^C, ^15^N\]--α-Synuclein in the absence (grey) and presence of 1mM of SecB-tetramer ((**f**), yellow) or 1mM of Skp-trimer ((**g**), red). Experiments were performed at 281 K and 310 K as indicated. The sequence-specific resonance assignment is shown. Experiments in panels **a--c** and **f--g** were done in duplicates yielding similar results.](EMS84680-f005){#F5}

![Chaperones Skp and Trigger Factor bind α-Synuclein at their native client sites.\
**a,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 250 μM \[*U*-^2^H,^15^N\]--Skp in the absence (grey) and presence of 750 μM α-Synuclein (red). **b,** Residue-resolved NMR signal intensity ratios (*I*~rel~ = *I*/*I*~0~) of Skp (250 μM) in the presence of three equivalents of α-Synuclein measured at 310K. The thin broken lines indicate a significance level of one standard deviation to the mean. The thick broken line represents an intensity ratio of 1. **c,** α-Synuclein induced intensity changes plotted on the Skp crystal structure (PDB 1SG2) ^[@R32]^ and earlier reported effects upon binding of its native client OmpX ^[@R10]^. Signal decrease of more than one standard deviation is highlighted in blue, whereas signal increase is highlighted in red. **d,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 250 μM \[*U*-^2^H,^15^N\]--Skp in the absence (grey) and presence of 500 μM BSA (blue). **e,** Residue-resolved NMR signal intensity ratios (*I*~rel~ = *I*/*I*~0~) of Skp (250 μM) in the presence of two equivalents of BSA measured at 310K. The thick broken line represents an intensity ratio of 1. **f,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 250 μM \[*U*-^2^H,^15^N\]--TF(ΔRBD), a monomeric Trigger Factor variant lacking its ribosome binding and main dimerization domain, in the absence (grey) and presence of 750 μM α-Synuclein (orange). **g,** Residue-resolved NMR signal intensity ratios (*I*~rel~ = *I*/*I*~0~) of 250 μM TF(ΔRBD) in the presence of three equivalents of α-Synuclein measured at 298K. The thin broken lines indicate a significance level of one standard deviation of the mean. The thick broken line represents an intensity quotient of 1. **h,** Residue-resolved combined chemical-shift differences of the amide moieties. The broken line indicates a significance level of two standard deviations of the mean. **i,** Significant chemical shift changes (green) and intensity decrease (blue) plotted on the Trigger Factor structure (PDB 1W26) ^[@R33]^. Comparison to the published Trigger Factor interaction-sites of PhoA (orange) ^[@R34]^. **j,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 250 μM \[*U*-^2^H,^15^N\]--TF(ΔRBD) in the absence (grey) and presence of 500 μM BSA (blue). **k,** Residue-resolved NMR signal intensity ratios (*I*~rel~ = *I*/*I*~0~) of TF(ΔRBD) (250 μM) in the presence of two equivalents of BSA measured at 298 K. The thick broken line represents an intensity ratio of 1. Experiments with α-Synuclein (panels **a** and **f**) were done as duplicates yielding similar results, whereas control experiments with BSA (panels **d** and **j**) were performed once.](EMS84680-f006){#F6}

![Interaction between α-Synuclein and mammalian proteins.\
**a,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 25 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 50 μM inhibited Hsp90β-dimer (light blue). Measured in NMR-buffer plus 5 mM MgCl~2~, 5 mM ATP, 1 μM Radicicol, and 1 μM Geldanamycin. **b,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 100 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 200 μM Hsc70 (light blue). **c,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 100 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 200 μM Hsc70~ADP~ (light blue). Measured in NMR-buffer plus 5 mM MgCl~2~ and 5 mM ADP. **d,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 100 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 200 μM Hsc70~ATP~ (light blue). Measured in NMR-buffer plus 5 mM MgCl~2~ and 5 mM ATP. **e,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 250 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 500 μM (33 mg/ml) BSA (blue). **f,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 250 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 500 μM of Ubiquitin (dark-blue). **g,** Residue-resolved combined chemical-shift perturbations of amide moieties upon addition of Hsp90β (cyan), inhibited Hsp90β (light cyan), Hsc70 (light-blue), Hsc70~ADP~ (light-blue), Hsc70~ATP~ (light-blue), BSA (blue), and Ubiquitin (dark blue). Broken lines indicate a significance level of two standard deviations of the mean. **h,** Residue-resolved backbone amide NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of α-Synuclein caused by the addition of two equivalents of inhibited Hsp90β (light cyan), Hsc70 (light blue), Hsc70~ATP~ (light blue), and BSA (blue). **i,** Residue-resolved NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of 100 μM \[*U*-^15^N\]--α-Synuclein upon addition of increasing BSA concentrations (50--250 mg/ml). **j,** Residue-resolved NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of 50 μM \[*U*-^15^N\]--α-Synuclein upon addition of increasing Ubiquitin concentrations (25--125 mg/ml). **k,** Local hydrophobicity of α-Synuclein plotted against the amino acid sequence. Δ*F* are the free energies of transfer of the individual amino acids from an aqueous solution to its surface ^[@R35]^. Hydrophobicity corresponds to negative Δ*F* values. An exponentially weighted 7-window average was applied to the raw data, with the edges contributing 50%. The red line indicates the average value of 1.5 standard deviations of the mean, the chosen threshold for the identification of the most hydrophilic segments. **l,** Sequence-dependent DnaK score for α-Synuclein derived from a computational DnaK prediction algorithm ^[@R36]^. Regions of the primary sequence with scores less than -5 (red line) are predicted to bind DnaK, a bacterial homolog of Hsc70. Experiments in panels **a--f** were done in duplicates with similar results.](EMS84680-f007){#F7}

![Kinetic analysis of the interaction of the chaperones with α-Synuclein variants.\
**a--c,** Kinetic analysis by BLI of biotinylated Skp (**a**), SecB (**b**), and Hsc70~ADP~ (**c**) to different α-Synuclein-variants (α-Synuclein (top), acetyl--α-Synuclein (middle), and ΔN--α-Synuclein (bottom). Black lines represent least-square fits to the data. Below each set of BLI-curves the residuals of the fits are shown. Each individual kinetic experiment was run twice in triplicates with similar results.](EMS84680-f008){#F8}

![Interaction between α-Synuclein and cellular extracts.\
**a,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 50 μM \[*U*-^15^N\]--α-Synuclein in the absence (black) and presence of 25 mg/ml μM of *E. coli* cell extract (green). **b,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 50 μM \[*U*-^15^N\]--α-Synuclein in the absence (black) and presence of 50 mg/ml mammalian MDCK-II cell extract (blue-green). **c,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of 50 μM \[*U*-^15^N\]--α-Synuclein in the absence (black) and presence of 50 mg/ml mammalian HEK-293 cell extract (green). **d,** Residue-resolved combined chemical-shift perturbations of the α-Synuclein amide moieties in *E. coli* cell extract (green), mammalian MDCK-II cell extract (blue), and mammalian HEK-293 cell extract (green), all relative to aqueous buffer. Broken lines indicate a significance level of two standard deviations of the mean. Experiments in panels **a--c** were done in duplicates with similar results.](EMS84680-f009){#F9}

![LUVs and the chaperone SecB compete for α-Synuclein binding.\
**a,** Residue-resolved backbone amide NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of α-Synuclein caused by the addition of 5 mg/ml LUVs (125:1 molar ratio lipid:protein; dark yellow) and after further addition of two equivalents of SecB (yellow). **b,** Residue-resolved backbone amide NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of α-Synuclein caused by the addition of 15 mg/ml LUVs (375:1 molar ratio lipid:protein; dark yellow) and after further addition of two and six equivalents of SecB, respectively (yellow), measured at 298 K. **c,** Residue-resolved backbone amide NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of α-Synuclein caused by the addition of 2 equivalents of SecB (yellow) and increasing amounts of LUVs with the following ratios: 2.5 mg/ml = 62.5:1, 4.0 mg/ml = 100:1, 6.25 mg/ml = 156:1, and 8.5 mg/ml = 212.5:1. **d,** Scheme showing the conformational equilibrium of free α-Synuclein, its chaperone-bound state, and one possible conformation of its LUV-bound state (PDB ID: 1XQ8) ^[@R19]^. Notably, these observations are also in full agreement with related studies for Hsp90 ^[@R12]^ and Hsp27 ^[@R37]^. **e,** Dynamic light scattering (DLS) measurements of LUVs prepared from pig brain polar lipids. Two independent preparations are shown in blue and orange, respectively, with an average diameter of 110 nm.](EMS84680-f010){#F10}

![In-cell interaction of α-Synuclein and chaperones.\
**a,** Western blot analysis of expression of α-Synuclein fused to a carboxy-terminal HA-tag in HEK-293 cells. The molecular weight marker and the band corresponding to α-Synuclein-HA are indicated. With these samples immunoprecipitation and subsequent mass-spectrometric analysis was performed ([Fig. 2a](#F2){ref-type="fig"}; Extended Data Fig. S7b). **b,** Intensity ratios of carboxy-terminally HA-tagged ΔN--α-Synuclein and α-Synuclein immune-precipitation determined by relative quantitative mass-spectrometry analysis. Experiments were performed as duplicates in HEK-293 cells. Identification of at least five peptides per protein was required for quantification. Values: Mean. The dotted line represents an intensity ratio of 1. Proteins belonging to specific groups are highlighted in colors. Further, the values for α-Synuclein (green) as well as Tubulin β4 and Tubulin α1B (orange arrows from left to right) are indicated by colored arrows. **c,** Efficiency of Hsc70 knockdown in HEK-293 cells (constitutively expressing the T-Rex repressor) stably transfected with an inducible shRNA targeting Hsc70 mRNA (shHsc70). The image shows a representative semi-quantitative RT-PCR of Hsc70 mRNA in cells treated with doxycycline to induce shHsc70 and Geldanamycin (Gel) and Radicicol (Rad) for 24 hours (+). Cells transfected with a control shRNA targeting firefly luciferase (shLUC) as well as semi-quantification of an unrelated chaperone (Hsp40) were included as negative controls. **d,** Semi-quantification of Hsc70 and Hsp90 protein levels by Western blot. HEK-293 cells (constitutively expressing the T-Rex repressor) stably transfected with shHsc70 and shLUC were grown in normal (-) or doxycycline containing (+) medium for Hsc70 knockdown. The cells were subsequently treated with vehicle (-) or Geldanamycin and Radicicol (Gel & Rad) for Hsp90 inhibition. The constitutively expressed protein GAPDH was assayed as loading control. **e**, Efficiency of the combined treatment of Geldanamycin and Radicicol in disrupting the α-Synuclein/Hsp90 interaction. HEK-293 cells were treated with Geldanamycin and Radicicol for 4 or 24 hours and then electroporated with recombinant α-Synuclein using the protocol for in-cell NMR experiments. Whole cell lysates were collected and used in immunoprecipitation assays with anti-α-Synuclein antibodies. The obtained precipitates were then resolved in SDS-PAGE and analyzed by Western blot using the indicated antibodies. In addition to HEK-293 cells with normal levels of Hsp90 (control cells), cells with reduced levels of Hsp90 (shHsp90) were used to validate the Hsp90 band. **f,** Inhibition of both Hsp90 and Hsc70 promotes α-Synuclein aggregation. The image shows a representative semi-quantitative Western blot of Hsc70-depleted HEK-293 cells treated with Geldanamycin and Radicicol. After 24 hours of treatment the cells were subjected to electroporation with recombinant α-Synuclein and 4 hours post electroporation the cells were harvested and subjected to Western blot. HMW and 14 kDa refer to high-molecular weight and monomeric α-Synuclein-species, respectively. **g**, **h**, Quantification of intracellular levels of Hsp90 and electroporated α-Synuclein in HEK-293 cells by Parallel Reaction Monitoring mass spectrometry (PRM). A standard curve (contained in the yellow boxes) using increasing amounts of recombinant Hsp90 (**g**) or α-Synuclein (**h**) serves for relative quantification of the intracellular protein levels. As surrogates for intracellular protein levels, at least four tryptic peptides of Hsp90 (**g**) or human α-Synuclein (**h**) were quantified. Targeted peptides are shown in the top of each plot, and at least four transitions of the y-series of the product ions were monitored over the chromatographic separation of the peptides (different colors). The determined cellular concentrations of Hsp90 and α-Synuclein were 30 μM and 2.5 μM, respectively (see [Supplementary Methods](#SD12){ref-type="supplementary-material"} section for details of this calculation). cps; counts per second. The original and uncropped gels of panels **a** as well as **c--f** can be found in [Supplementary Figure 1](#SD12){ref-type="supplementary-material"}. Western Blot and PCR experiments (panels **a, c--f**) were done in duplicates resulting in similar results.](EMS84680-f011){#F11}

![Sequence-specific NMR-resonance assignments of α-Synuclein variants.\
**a--c,** 2D \[^15^N,^1^H\]-NMR spectra of 500 μM \[*U*-^13^C,^15^N\]--α-Synuclein (grey), 450 μM \[*U*-^13^C,^15^N\]--acetyl--α-Synuclein (dark-violet), and 100 μM \[*U*-^15^N\]--ΔN--α-Synuclein (dark blue). The sequence-specific resonance assignments for wild-type as well as acetylated--α-Synuclein obtained from 3D triple resonance experiments and from chemical shift mapping for ΔN--α-Synuclein are indicated. **d, e,** 2D \[^13^C,^15^N\]-NMR spectra of 500 μM \[*U*-^13^C,^15^N\]--α-Synuclein (grey) and 450 μM \[*U*-^13^C,^15^N\]--acetyl--α-Synuclein (dark-violet). The sequence-specific resonance assignments for wild-type and acetylated--α-Synuclein obtained from 3D triple resonance experiments are indicated. **f,** Residue-resolved combined chemical-shift perturbations of the amide moieties for acetyl--α-Synuclein (dark violet) and ΔN--α-Synuclein (dark blue) *vs.* wild-type α-Synuclein. **g,** Residue-resolved combined chemical-shift difference of the carbonyl-amide moieties for acetyl--α-Synuclein (dark violet) *vs.* wild-type α-Synuclein. \[^15^N,^1^H\]-NMR spectra in panels **a--c** were measured several times (n=5), and \[^13^C,^15^N\]-NMR spectra (panels **d, e**) were measured in duplicates, all yielding similar results.](EMS84680-f012){#F12}

![Sequence-specific NMR-resonance assignments of methionine-oxidized and tyrosine-phosphorylated α-Synuclein variants.\
**a--c,** 2D \[^15^N,^1^H\]-NMR spectra of 100 μM \[*U*-^15^N\]--oxidized--α-Synuclein (light grey), 100 μM \[*U*-^15^N\]--oxidized-acetyl--α-Synuclein (violet), and 100 μM \[*U*-^15^N\]--oxidized-ΔN--α-Synuclein (blue). The sequence-specific resonance assignments from chemical shift mapping and published assignments of the oxidized state ^[@R23]^ are indicated. Oxidized methionines are highlighted in red. **d,** Residue-resolved combined chemical-shift differences of the amide moieties for oxidized--α-Synuclein (light grey), oxidized-acetyl--α-Synuclein (violet), and oxidized-ΔN--α-Synuclein (blue) relative to their respective reduced states. Colors as in panels **a--c**. Arrows indicate the positions of the oxidized methionines. **e--g,** 2D \[^15^N,^1^H\]-NMR spectra of 50 μM \[*U*-^15^N\]--mono-phospho--α-Synuclein (red-brown), 50 μM \[*U*-^15^N\]--tri-phospho--α-Synuclein (brown), and 50 μM \[*U*-^15^N\]--tetra-phospho--α-Synuclein (dark brown). The sequence-specific resonance assignments based on published assignments for phosphorylated α-Synuclein are indicated ^[@R24]^. Phosphorylated residues are highlighted in cyan. **h,** Residue-resolved combined chemical-shift differences of the amide moieties for the phosphorylated--α-Synuclein variants relative to wild-type α-Synuclein. Colors as in panels **e--g**. Arrows indicate the positions of the phosphorylated tyrosines. \[^15^N,^1^H\]-NMR spectra of the different modified α-Synuclein variants were measured several times (n=4) yielding similar results.](EMS84680-f013){#F13}

![Mechanism of chaperone-controlled regulation of α-Synuclein function, conformation, and localization, in mammalian cells.\
Cellular chaperones (yellow) interact with the amino-terminal segment of α-Synuclein (red), thus actively regulating its functional species by shifting conformational equilibria. Impairing the natural α-Synuclein--chaperone ratio or deteriorations of the α-Synuclein--chaperone interaction by post-translational modifications can consequently favor the formation of pathological species, including the association of α-Synuclein to mitochondria.](EMS84680-f014){#F14}
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![Molecular chaperones delay α-Synuclein aggregation by interaction with its amino-terminus.\
**a, b,** ThT emission curves of 300 μM α-Synuclein in the presence of chaperones (15 μM in (**a**) and 30 μM in (**b**)). **c,** ThT emission curves of 100 μM α-Synuclein in the presence of 5 μM Hsp90β with and without addition of 1 μM of Drugs. In panels **a-c**, mean values are given with SD (n=3). **d,** Overlay of 2D \[^15^N, ^1^H\]-NMR spectra of 250 μM \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of 500 μM of SecB-tetramer (yellow) (n=3, with similar results). **e,** Residue-resolved backbone amide NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of α-Synuclein upon addition of two equivalents of either SecB tetramer (yellow), Trigger Factor dimer (orange), Skp trimer (red), and SurA dimer (dark red). **f,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of \[*U*-^15^N\]--α-Synuclein in the absence (grey) and presence of two equivalents Hsp90β-dimer (cyan) (n=2, with similar results). **g, h,** Residue-resolved backbone amide NMR signal attenuation (*I*~rel~ = *I*/*I*~0~) of α-Synuclein upon addition of two equivalents of Hsp90β-dimer (cyan), Hsc70~ADP~ (light-blue), and Ubiquitin (dark blue) as well as *E. coli* cell-extract (green), mammalian MDCK-II cell-extract (blue), and mammalian HEK-293 cell-extract (green). In panels **e**, **g**, and **h**, values \< 1.0 are indicative of intermolecular interactions.](EMS84680-f001){#F1}

![The interaction between α-Synuclein and chaperones is dominant in living cells.\
**a,** Abundance ratios of proteins bound to ΔN--α-Synuclein *vs.* wild-type full-length α-Synuclein determined by relative quantitative mass-spectrometry (mean values, n=2). **b,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of \[*U*-^15^N\]--α-Synuclein in NMR-buffer (black) and inside living HEK-293 cells (blue-green). Representative spectrum from n\>5. **c,** Residue-resolved backbone amide NMR signal attenuation (*I~HEK~*/*I*~Buffer~) of α-Synuclein in mammalian cells. **d,** In-cell NMR signal attenuation in differently treated cells, relative to untreated cells (*I/I~HEK~*). Different combinations of Hsc70-depletion and Hsp90β-inhibition were applied, as indicated. **e, f,** Overlay of 2D \[^15^N,^1^H\]-NMR spectra of \[*U*-^15^N\]--α-Synuclein in untreated HEK-293 cells (black) and in Hsc70-depleted HEK-293 cells (green)(**e**) or in Hsc70-depleted HEK-293 cells after 24 hours of Hsp90β-inhibition (green) (**f**). Representative data (**d--f**) for three technical replicates yielding similar results.](EMS84680-f002){#F2}

![Co-localization of α-Synuclein and cellular organelles by immunofluorescence.\
**a--f,** Immunofluorescence analysis of α-Synuclein electroporated into HEK-293 cells. Cells were either untreated (shLuc) or treated for a combined depletion of Hsc70 and Hsp90β (shHsc70 + Drugs). Cells were either stained with mitotracker (red; **a**) to stain mitochondria, or with WGA (red; **b**) to stain the plasma membrane and the endoplasmatic reticulum or lysotracker (red, **c**) to stain acidic vesicles such as lysosomes, DAPI (blue) to stain cell nuclei, and an α-Synuclein specific antibody (green). Dashed boxes indicate areas of intense signal for mitotracker and α-Synuclein. **d,** Cox IV (red, mitochondrial marker) and α-Synuclein (green) were visualized by specific antibodies, nuclei were stained by DAPI (blue). Dashed circles labeled a or a' indicate cells with high α-Synuclein content, brackets labeled b or b' indicate cells with low α-Synuclein content. **e, f**, Control HEK-293 cells (shLuc; **e**) or HEK-293 cells treated for the combined knock-down of Hsc70 and Hsp90β (shHsc70 + Drugs; **f**) were stably transfected with an expression plasmid containing the gene of mitochondria-targeted blue fluorescent protein (mtBFP). Cells were fixed and subjected to immunofluorescence analyses using an anti-α-Synuclein antibody. Propidium iodide (PI) was used to stain cells un-specifically allowing visualization of cell morphology. Note, the blue color originating from mtBFP was changed to green to better visualize mtBFP/α-Synuclein co-localization. Scale bar in all panels: 10 μm. Experiments were performed twice yielding similar results.](EMS84680-f003){#F3}

![Effect of post-translational modifications on the chaperone--α-Synuclein interaction.\
**a,** Cartoon representation of differently modified α-Synuclein variants as indicated. **b, c, d, and e**, Residue-resolved backbone amide NMR signal attenuation (Δ*I*~rel~ = 1--*I*/*I*~0~) of the α-Synuclein variants upon interaction with two equivalents of Hsp90β dimer (**b**), Hsc70~ADP~ (**c**), SecB tetramer (**d**) or Skp trimer (**e**). Elevated Δ*I*~rel~ values are indicative of an interaction.](EMS84680-f004){#F4}
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